RELYBO PHARMACHEMICAL CO.,LTD. ("RELYBO" for short, while the word of RELYBO comes from "reliable" by a similar glyph and pronunciation) has always been focusing on the field of pharmaceuticals and chemicals, mainly engaged in APIs & Intermediates, Fine Chemicals, Basic Chemicals, Agrochemicals and Organic Solvents, etc.
                    Since its establishment, RELYBO has already been keeping stable development of business, while its products are exported to Europe, North America, Asia, Africa and Latin America, and RELYBO enjoys a good reputation at home and abroad. After years of unremitting efforts, RELYBO has established strategic cooperation with many well-known R&D institutions in China, and also established production bases of Organic Fluorine Chemistry and Organic Sulfur Chemistry Separately in Fuxin, Liaoning Province and Yangcheng, Shanxi Province. Thus, RELYBO has changed from a single trade-oriented company to a diversified comprehensive enterprise integrating R&D, production and trade. 
                    RELYBO has an excellent team, which is professional, efficient and dynamic, while this team started in 2004. It is worth mentioning that RELYBO became a member enterprise of "DUDLEY CHEM" in 2019, which brought RELYBO to reorganize and establish some core divisions / departments such as Pharmachemical Division, Agrochemical Division, Marketing Department and so on. Looking forward to greater development of RELYBO in the future!
                    Adhering to the business philosophy of "Development & Innovation, based on the Market; Honesty & Pragmatism, loyal to the Commitment" and with the mission of "Pursuing Customer Satisfaction and Creating Greater Value for Customers", RELYBO is always providing customers with high-quality products and first-class services! 
                    LONDON, May 22 (Xinhua) -- China's COVID-19 vaccine trial, the first such vaccine to reach phase 1 clinical trial, has been found to be safe, well-tolerated, and able to generate an immune response against SARS-COV-2 in humans, according to a study published online on Friday by medical journal The Lancet.

                    The open-label trial in 108 healthy adults demonstrates promising results after 28 days and the final results will be evaluated in six months, The Lancet said in a press statement. Further trials are needed to tell whether the immune response it elicits effectively protects against SARS-COV-2 infection, said the medical journal.

                    "These results represent an important milestone. The trial demonstrates that a single dose of the new adenovirus type 5 vectored COVID-19 (Ad5-nCoV) vaccine produces virus-specific antibodies and T cells in 14 days, making it a potential candidate for further investigation," said Professor Wei Chen from the Beijing Institute of Biotechnology in Beijing, China, who is responsible for the study.

                    "However, these results should be interpreted cautiously. The challenges in the development of a COVID-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. This result shows a promising vision for the development of COVID-19 vaccines, but we are still a long way from this vaccine being available to all," said Chen.

                                                                                                                                           From Xinhua
                    • TOKYO - Japan on Thursday approved Gilead Sciences Inc's remdesivir as a treatment for COVID-19, making it the country's first officially authorized drug to tackle the coronavirus disease.

                      Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

                      "There has so far been no coronavirus medicine available here so it is a significant step for us to approve this drug," a Japanese health ministry official said at a press briefing. Remdesivir will be give to patients with severe COVID-19 symptoms, he added.

                      With no other approved treatments for COVID-19, interest in the drug is growing around the world. Administered by intravenous infusion, it was granted authorisation last week by the US Food and Drug Administration for emergency use for the disease caused by the novel coronavirus.

                      Gilead says the drug has improved outcomes for people suffering from the respiratory disease and has provided data suggesting it works better when given in the early stages of infection.

                      Japan, with just over 16,000 infections and under 800 deaths, has recorded fewer cases than other major industrialized nations.

                      However, a steady rise in cases has put pressure on medical facilities in some parts of the country, and a drug that helps patients recover more quickly could help in freeing up hospital beds.

                      A trial performed by the US Institutes of Health (NIH) showed the drug cut hospital stays by 31% compared with a placebo treatment, although it did not significantly improve survival.

                      On Monday, Japanese Prime Minister Shinzo Abe extended a month-long state of emergency until the end of May in an attempt to slow the spread of the coronavirus.

                      Japan as yet does not know when it will get its first doses of remdesivir or how much, the health ministry official said.

                      Gilead on Tuesday said it was in discussion with several companies, including generic drugmakers in India and Pakistan to produce remdesivir in large quantities.

                      Remdesivir, which previously failed as a treatment for Ebola, is designed to disable the ability by which some viruses make copies of themselves inside infected cells.

                                                                                                                                From China Daily 2020-05-07
                    • FOSTER CITY, Calif. (BUSINESS WIRE) Apr. 29, 2020 -- Gilead Sciences, Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing.

                      Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19. Gilead will share additional remdesivir data from the company’s open-label Phase 3 SIMPLE trial in patients with severe COVID-19 disease shortly. This study will provide information on whether a shorter, 5-day duration of therapy may have similar efficacy and safety as the 10-day treatment course evaluated in the NIAID trial and other ongoing trials. Gilead expects data at the end of May from the second SIMPLE study evaluating the 5- and 10-day dosing durations of remdesivir in patients with moderate COVID-19 disease.

                      Gilead will continue to discuss with regulatory authorities the growing data set regarding remdesivir as a potential treatment for COVID-19.

                      About Remdesivir

                      Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS. In vitro testing conducted by Gilead has demonstrated that remdesivir is active against the virus that causes COVID-19. The safety and efficacy of remdesivir for the treatment of COVID-19 are being evaluated in multiple ongoing Phase 3 clinical trials.

                      About Gilead Sciences

                      Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

                                                                                                                                     From Gilead Sciences
                    • Amsterdam, 20 April 2020 -- CPhI & P-MEC China 2020, the landmark 20th anniversary edition of China's largest pharma exhibition, will now take place on 16-18 December 2020 at SNIEC in Shanghai [rescheduled from June 22-24, 2020].

                      The organizers secured the new date at the request of exhibitors to ensure the event's very strong international profile. A quarter of CPhI & P-MEC China's attendees come from international markets, and its global audience is a key component to many companies'strategies in the region.

                      The new date will provide greater access to international audiences, as at present, strict travel restrictions remain in place for all intentional visitors to China in response to COVID-19.

                      “By moving the event to a December date, we provide far greater flexibility and planning time for international executives. CPhI & P-MEC China has grown massively in the last few years and it remains the only truly international pharma ingredients and supply chain event in China, with more than 20,300 visits from overseas attendees. Rather than host a predominately local event, we decided to respond to the needs of our clients and partners, moving to a time when the event's unique international pedigree can be better maintained,” commented Orhan Caglayan, Brand Director Pharma Portfolio at Informa Markets.

                      Apart from the offline exhibition in December, a seven-day online model of the exhibition is scheduled to be held during 18-24 June to break the physical restrictions and facilitate unlimited connections among global pharmaceutical companies.

                      The organizers continue to listen to exhibitor feedback and are monitoring the global situation extremely closely in order to keep the industry informed. Caglayan added,  “It's our absolute priority to follow government advice globally and deliver safe and successful events. But we also want to take a proactive approach so that we can ensure the integrity and quality of the platforms we provide for both exhibitors and visitors.”

                                                                                                                                         From CPhI China
                    Production Bases
                    Links:   DUDLEY CHEM     Xintu Chemical    
                    Copyright: RELYBO PHARMACHEMICAL CO.,LTD.    Add: No.4 Lvdu Ave., Nanjing(210012), Jiangsu, China    蘇ICP備20010078號Tel: +86-25-87716566    E-mail: sales@relybopharma.com
                    Copyright: RELYBO PHARMACHEMICAL CO.,LTD.